🧬 AI, Mechanisms, & the Next Wave of Drug Discovery | David Li Rerelease (4/4)

David Li explains how a research question about mischaracterized drug targets became the starting point for Meliora Therapeutics. He describes how CRISPR experiments and follow-up biology challenged the accepted mechanism for cancer drugs, and how the company uses AI and machine learning to connect chemistry, biology, biomarkers, and patient populations.